AMENDMENTS TO THE CLAIMS

Please add claims 17-27 as shown in the following listing of claims, which will replace all prior versions and listings of claims in the application.

Listing of claims:

1 (previously presented). A method of treating basal cell carcinoma in a subject, the method comprising administering to the subject an amount of an IRM compound effective for treating basal cell carcinoma wherein the IRM compound is administered in a treatment cycle that comprises at least five consecutive days in which the IRM compound is administered and at least two days in which the IRM compound is not administered.

2. - 6. (canceled)

7 (original). The method of claim 1 wherein the method comprises at least two treatment cycles.

8 (original). The method of claim 7 wherein the method comprises at least six treatment cycles.

9 (original). The method of claim 1 wherein administering the IRM compound comprises applying one dose of the IRM compound per day.

10 (original). The method of claim 1 wherein administering the IRM compound comprises topically applying the IRM compound to a treatment area that includes a lesion.

- 11 (original). The method of claim 10 wherein the IRM compound is applied in a formulation that comprises from about 1% to about 10% IRM compound.
- 12 (original). The method of claim 11 wherein the formulation comprises about 5% IRM compound.
- 13 (original). The method of claim 11 wherein the formulation is applied to the treatment area for from about two hours to about 24 hours.
- 14 (original). The method of claim 13 wherein the formulation is applied to the treatment area for from about six hours to about twelve hours.
- 15 (original). The method of claim 11 wherein the formulation is applied to the treatment area for about eight hours.
- 16 (original). The method of claim 10 wherein the treatment area further comprises skin at least 0.5 cm beyond the margin of the lesion.
- 17 (new). The method of claim 1, wherein the IRM compound comprises an imidazoquinoline.
- 18 (new). The method of claim 1, wherein the IRM compound comprises an imidazoquinoline amine or an imidazoquinoline amide.
- 19 (new). The method of claim 18, wherein the IRM compound comprises 1-(2-methylpropyl)-1*H*-imidazo[4,5-*c*]quinolin-4-amine.

- 20 (new). The method of claim 1, wherein the basal cell carcinoma comprises superficial basal cell carcinoma.
- 21 (new). A method of treating basal cell carcinoma in a subject, the method comprising administering to the subject an amount of an IRM compound effective for treating basal cell carcinoma wherein the IRM compound is administered in a treatment cycle that comprises at least five consecutive days in which the IRM compound is administered and at least two days in which the IRM compound is not administered, wherein:
 - (a) the method comprises at least six treatment cycles;
 - (b) administering the IRM compound comprises topically applying one dose of the IRM compound per day to a treatment area that includes a lesion;
 - (c) the IRM compound is applied in a formulation that comprises from about 1% to about 10% IRM compound;
 - (d) the formulation is applied to the treatment area for from about six hours to about twelve hours;
 - (e) the IRM compound comprises an the IRM compound comprises an imidazoquinoline amine or an imidazoquinoline amide.
- 22 (new). The method of claim 21, wherein the formulation comprises about 5% IRM compound.
- 23 (new). The method of claim 21, wherein the formulation is applied to the treatment area for about eight hours.
- 24 (new). The method of claim 21, wherein the treatment area further comprises skin at least 0.5 cm beyond the margin of the lesion.

- 25 (new). The method of claim 21, wherein the IRM compound comprises 1-(2-methylpropyl)-1*H*-imidazo[4,5-*c*]quinolin-4-amine.
- 26 (new). The method of claim 1, wherein the basal cell carcinoma comprises superficial basal cell carcinoma.
- 27 (new). A method of treating superficial basal cell carcinoma in a subject, the method comprising administering to the subject an amount of an IRM compound effective for treating superficial basal cell carcinoma wherein the IRM compound is administered in a treatment cycle that comprises at least five consecutive days in which the IRM compound is administered and at least two days in which the IRM compound is not administered, wherein:
 - (a) the method comprises at least six treatment cycles;
 - (b) administering the IRM compound comprises topically applying one dose of the IRM compound per day to a treatment area that includes a lesion;
 - (c) the IRM compound is applied in a formulation that comprises about 5% IRM compound;
 - (d) the formulation is applied to the treatment area for from about six hours to about twelve hours;
 - (e) the IRM compound comprises an the IRM compound comprises imiquimod.
- 28 (new). The method of claim 27, wherein the formulation is applied to the treatment area for about eight hours.
- 29 (new). The method of claim 27, wherein the treatment area further comprises skin at least 0.5 cm beyond the margin of the lesion.